AAAP Advanced Accelerator Applicatio

28.91
+0.3  (1.05%)
Previous Close 28.61
Open 28.65
Price To book 6.47
Market Cap 1.14B
Shares 39,278,000
Volume 66,091
Short Ratio 1.11
Av. Daily Volume 99,036

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated September 2016
Apoptosis
Necrosis
Phase 2 initiated September 2016
Annexin V-128
Apoptosis
Positive opinion by EMA released in October 2016.
Somakit-TOC
Neuroendocrine cancers
PDUFA date under priority review was December 28, 2016. CRL issued December 21, 2016.
Lutathera
Inoperable progressive midgut NETs
Approved June 1 2016
Somakit-TATE
Neuroendocrine tumor diagnosis
Ongoing
Annexin V-128
Rheumatoid arthritis and ankylosing spondylitis

Latest News

  1. Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results
  2. ETFs with exposure to Advanced Accelerator Applications SA : January 11, 2017
  3. Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera® NDA
  4. Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference
  5. Advanced Accelerator Applications downgraded by JMP Securities
  6. Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
  7. Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
  8. Advanced Accelerator Applications Announces European Commission Approval of SomaKit TOC™
  9. Is Advanced Accelerator Application SA (ADR) (AAAP) a Good Stock to Buy?
  10. Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code for its First FDA Approved Drug NETSPOT®
  11. Is Herc Holdings Inc. (HRI) Worthy of Your Portfolio?
  12. Aclaris Therapeutics (ACRS) Worth Watching: Stock Up 7.5%
  13. Advanced Accelerator Applications SA :AAAP-US: Earnings Analysis: Q3, 2016 By the Numbers : November 29, 2016
  14. Edited Transcript of AAAP earnings conference call or presentation 28-Nov-16 9:30pm GMT
  15. Investor Calendar Invites You to the Advanced Accelerator Applications Third Quarter 2016 Earnings Conference Call and Webcast Live on Monday, November 28, 2016
  16. IntelliPharmaCeutics (IPCI) Jumps: Stock Adds 5% in Session
  17. Q3 2016 Advanced Accelerator Applications SA Earnings Release - Before Market Open
  18. Advanced Accelerator Applications Reports 15.4% Sales Growth in the Third Quarter of 2016 and Feedback from the FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors
  19. The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3
  20. Advanced Accelerator Applications to Announce Third Quarter and Nine-Month 2016 Financial Results on November 28
  21. Advanced Accelerator Applications to Announce Third Quarter and Nine-Month 2016 Financial Results on November 28
  22. Patterson Companies (PDCO) Q2 Earnings: What's in Store?
  23. Xencor (XNCR) Looks Good: Stock Adds 13.2% in Session
  24. Why Concordia International (CXRX) Could Be Positioned for a Slump
  25. Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products
  26. Advanced Accelerator Applications S.A. Announces Pricing of $150 Million Public Offering of American Depositary Shares
  27. Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC
  28. Advanced Accelerator Applications Announces Presentations on Lutathera® NETTER-1 Phase III and NeoBOMB1 at EANM
  29. Advanced Accelerator Applications S.A. Announces Pricing of $150 Million Public Offering of American Depositary Shares
  30. Advanced Accelerator Applications S.A. Announces Pricing of $150 Million Public Offering of American Depositary Shares
  31. Advanced Accelerator Applications S.A. Announces Proposed Public Offering of American Depositary Shares
  32. EMA Prematurely Announced Opinion on SomaKit TOC® Kit Application
  33. Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera®
  34. Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC Kit for Radiopharmaceutical Preparation of Gallium (Ga 68) Edotreotide for Gastroenteropancreatic Neuroendocrine Tumor Detection
  35. Advanced Accelerator Applications Announces Two Phase II Studies Evaluating 99MTc-rhAnnexin V-128 Imaging in Cardiovascular and Cardio-Oncology Indications at University of Ottawa Heart Institute and Ottawa Hospital
  36. Advanced Accelerator Applications Announces Two Phase II Studies Evaluating 99MrhAnnexin V-128 Imaging in Cardiovascular and Cardio-Oncology Indications at University of Ottawa Heart Institute and Ottawa Hospital
  37. Fundraising, Directorate Change and Operational Update
  38. Advanced Accelerator Applications Reports 24.4% Sales Growth in the Second Quarter of 2016 – Launches First U.S. Product and Continues Momentum with Pipeline
  39. Form 8 (Opening Position Disclosure)
  40. Advanced Accelerator Applications Announces First Administration of NETSPOT™ at Holy Name Medical Center
  41. Advanced Accelerator Applications Announces First Administration of NETSPOT at Holy Name Medical Center
  42. Advanced Accelerator Applications Announces Clinical Trial Agreement with National Cancer Institute for Study of Lutathera in Patients with Inoperable Pheochromocytoma and Paraganglioma